/
NTRA
$271.45-$0.86 (-0.32%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$37.5B
143M shares
52-week range
$131.81 – $275.24
97% from low
Sector
SERVICES-MEDICAL LABORATORIES
Exchange
NASDAQ
CS
Borrow rate
0.40%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$155.39
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $257.7M | $302.3M | $391.0M | $625.5M | $820.2M | $1.08B | $1.70B | $2.31B |
| Cost of revenue | $166.1M | $175.5M | $203.6M | $318.4M | $456.3M | $589.8M | $673.8M | $810.6M |
| Gross profit | $91.6M | $126.9M | $187.4M | $307.1M | $364.0M | $492.7M | $1.02B | $1.50B |
| Gross margin | 35.6% | 42.0% | 47.9% | 49.1% | 44.4% | 45.5% | 60.3% | 64.8% |
| R&D | $51.4M | $51.4M | $100.0M | $264.2M | $316.4M | $320.7M | $404.1M | $624.1M |
| Operating income | −$114.6M | −$116.3M | −$216.3M | −$468.2M | −$541.0M | −$446.2M | −$222.3M | −$309.9M |
| EBITDA | −$107.1M | −$104.4M | −$205.9M | −$451.5M | −$507.0M | −$383.3M | −$148.1M | −$220.5M |
| Net income | −$128.2M | −$124.8M | −$229.7M | −$471.7M | −$547.8M | −$434.8M | −$190.4M | −$208.2M |
| Net margin | -49.7% | -41.3% | -58.8% | -75.4% | -66.8% | -40.2% | -11.2% | -9.0% |
| EPS (diluted) | -2.22 | -1.79 | -2.84 | -5.21 | -5.57 | -3.78 | -1.53 | -1.52 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $2.8B | $-1.62 | $-1.81–$-1.51 | 11 |
| 2027 | $3.3B | $-0.30 | $-1.51–$0.90 | 12 |
| 2028 | $4.0B | $1.50 | $-1.21–$4.61 | 13 |
| 2029 | $4.7B | $2.29 | $2.20–$2.36 | 11 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Natera, Inc. Common Stock
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
www.natera.com- Employees
- 6,140
- IPO / List date
- Jul 2, 2015
- HQ
- AUSTIN, TX
Held by traders on TradeandTell
No one on the platform currently holds NTRA.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 197,500 | $39.5M |
| Bridgewater Associatesas of 2026-03-31 | 25,237 | $5.0M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded NTRA yet.
